Your browser doesn't support javascript.
loading
Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer.
Harrod, Julia C; Cheung, Yee-Ming M; Buckley, Lauren; Cromwell, Grace E; Fowler, Kristen M; Hughes, Melissa E; Lin, Nancy U; Tolaney, Sara M; Min, Le; McDonnell, Marie E.
Afiliación
  • Harrod JC; Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Cheung YM; Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Buckley L; Division of Endocrinology, Diabetes and Metabolism, Northwell Health, Manhasset, New York, USA.
  • Cromwell GE; Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Fowler KM; Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Hughes ME; Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Lin NU; Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Tolaney SM; Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Min L; Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • McDonnell ME; Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Diabet Med ; 41(4): e15292, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38291604
ABSTRACT

AIMS:

In patients with breast cancer (BCa) and diabetes (DM), diabetes distress (DD) and treatment satisfaction (DTS) can influence BCa management and outcomes. We assessed the impact of implementing a personalized diabetes care model in patients with BCa.

METHODS:

Patients in active treatment or surveillance for BCa with an HbA1c > 53 mmol/mol (7%) or random blood glucose >11.1 mmol/L were included. Participants were offered continuous glucose monitoring (CGM), virtual care and a dedicated diabetes provider for 6 months. Primary outcomes included DD measured by the Diabetes Distress Survey (DDS) and DTS measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Questionnaires were conducted at 0, 3 and 6 months.

RESULTS:

Thirty-one women were enrolled (median age 61, IQR 49.0-69.0). Compared to baseline, the mean DDS score was lower at both 3 months (2.2 vs. 1.8 [n = 27], p = 0.004, SD = 0.70) and 6 months (2.3 vs. 1.8 [n = 23], p = 0.002, SD = 0.70). The mean DTSQ score was higher at 3 months (baseline 20.5 vs. 3 months 28.7 [n = 28], p < 0.001, SD = 9.2) and 6 months (baseline 20.4 vs. 6 months 30.0 [n = 26], p < 0.001, SD = 9.7).

CONCLUSIONS:

Personalized diabetes care models that emphasize remote management and optimize access for those with BCa may lower DD and improve DTS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Diabetes Mellitus / Diabetes Mellitus Tipo 1 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Diabet Med Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Diabetes Mellitus / Diabetes Mellitus Tipo 1 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Diabet Med Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos